Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Intercept Pharmaceuticals, Inc. (ICPT)

19.01   -0.14 (-0.73%) 02-03 13:55
Open: 18.79 Pre. Close: 19.15
High: 19.29 Low: 18.73
Volume: 191,244 Market Cap: 787(M)

Technical analysis

as of: 2023-02-03 1:47:23 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 22.53     One year: 26.31
Support: Support1: 14.56    Support2: 11.64
Resistance: Resistance1: 19.29    Resistance2: 22.53
Pivot: 17.37
Moving Average: MA(5): 18.72     MA(20): 16.83
MA(100): 14.96     MA(250): 15.5
MACD: MACD(12,26): 1.2     Signal(9): 1
Stochastic oscillator: %K(14,3): 95.4     %D(3): 91.9
RSI: RSI(14): 72.5
52-week: High: 21.25  Low: 10.81
Average Vol(K): 3-Month: 723 (K)  10-Days: 562 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ICPT ] has closed below upper band by 17.9%. Bollinger Bands are 51.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.29 - 19.36 19.36 - 19.45
Low: 18.45 - 18.53 18.53 - 18.62
Close: 19 - 19.13 19.13 - 19.28

Company Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Headline News

Fri, 03 Feb 2023
Barclays PLC Increases Stock Holdings in Intercept ... - MarketBeat

Thu, 02 Feb 2023
State Street Cuts Stake in Intercept Pharmaceuticals (ICPT) - Nasdaq

Tue, 31 Jan 2023
BlackRock Updates Holdings in Intercept Pharmaceuticals (ICPT) - Nasdaq

Wed, 25 Jan 2023
ICPT Stock Pops After Intercept Staves Off Amneal's Ocaliva ... - Investor's Business Daily

Wed, 25 Jan 2023
Do Analysts Agree Wednesday on Intercept Pharmaceuticals Inc (ICPT) Stock's Target Price? - InvestorsObserver

Thu, 19 Jan 2023
Strs Ohio Trims Stock Position in Intercept Pharmaceuticals, Inc ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 41 (M)
Shares Float 34 (M)
% Held by Insiders 3.1 (%)
% Held by Institutions 81.1 (%)
Shares Short 3,530 (K)
Shares Short P.Month 3,530 (K)

Stock Financials

EPS -2.21
EPS Est Next Qtl -3.45
EPS Est This Year -13.99
EPS Est Next Year -11.6
Book Value (p.s.) 2.59
Profit Margin (%) 54.3
Operating Margin (%) -9
Return on Assets (ttm) -4
Return on Equity (ttm) 0
Qtrly Rev. Growth 16.3
Gross Profit (p.s.) 8.7
Sales Per Share 9.17
EBITDA (p.s.) -0.8
Qtrly Earnings Growth 0
Operating Cash Flow -17 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -8.7
PEG Ratio -0.5
Price to Book value 7.35
Price to Sales 2.08
Price to Cash Flow -45.62

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.